Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) recently presented data on two of its PSMA-focused technologies, at the European Association of Nuclear Medicine (EANM) Annual Congress in Lyon, France (October 21), and the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston (October 19 - 23).
At EANM's Annual Congress, Dr. Shankar Vallabhajosula, Professor of Radiochemistry at Cornell Medical College, presented data from a phase 1 clinical study of eight patients undergoing radical prostatectomy. In these patients, 99mTc-MIP 1404, a radiopharmaceutical imaging agent candidate currently in a phase 2 international multicenter study by Progenics' Molecular Insight subsidiary, detected primary metastatic prostate cancer and metastatic lesions in both soft tissue and bone with high specificity. 99mTc uptake in lesions correlated well with both Gleason Scores and PSMA expression in the phase 1 study.
At the AACR Conference, Progenics scientists Jose Murga and Yakov Rotshteyn presented findings from studies of PSMA ADC, the company's antibody-drug conjugate candidate in a phase 2 study for the treatment of metastatic castration-resistant prostate cancer.
Additional data and information are included in the presentations which are available for the next 30 days in the Media Center of the company's website, www.progenics.com.
Hopefully a base is now forming and we move up approaching March date. The RSI on the chart is oversold so there shouldn't be too much more downside.